When and how ruling out cystic fibrosis in adult patients with bronchiectasis

Andrea Gramegna 1, Stefano Aliberti 1*, Manuela Seia 2, Luigi Porcaro 2, Vera Bianchi 3, Carlo Castellani 4, Paola Melotti 4, Claudio Sorio 5, Enza Consalvo 2, Elisa Franceschi 1, Francesco Amati 1, Martina Contarini 1, Michele Gaffuri 6, Luca Roncoroni 6, Barbara Vigone 7, Angela Bellofiore 1, Cesare Del Monaco 1, Martina Oriano 1,9, Leonardo Terranova 8, Maria Francesca Patria 8, Paola Marchisio 8, Baroukh M. Assael 1 and Francesco Blasi 1

From 2nd World Bronchiectasis Conference
Milan, Italy. 06-08 July 2017

Abstract

Background: Bronchiectasis is the final result of different processes and most of the guidelines advocate for a careful evaluation of those etiologies which might be treated or might change patients’ management, including cystic fibrosis (CF).

Main body: CFTR mutations have been reported with higher frequency in bronchiectasis population. Although ruling out CF is considered as a main step for etiological screening in bronchiectasis, CF testing lacks of a standardized approach both from a research and clinical point of view. In this review a list of most widely used tests in CF is provided.

Conclusions: Exclusion of CF is imperative for patients with bronchiectasis and CFTR testing should be implemented in usual screening for investigating bronchiectasis etiology. Physicians taking care of bronchiectasis patients should be aware of CFTR testing and its limitations in the adult population. Further studies on CFTR expression in human lung and translational research might elucidate the possible role of CFTR in the pathogenesis of bronchiectasis.

Keywords: Bronchiectasis, CFTR, Etiological screening, CFTR gene analysis, Sweat test

Background

Bronchiectasis is a chronic respiratory disease characterized by a permanent dilation of the bronchi associated with cough, daily sputum production and recurrent episodes of respiratory infections [1]. Although studies probably underestimate the true prevalence of bronchiectasis, recent literature suggests bronchiectasis as far from being a rare disease [2]. Different European datasets describes a prevalence of bronchiectasis ranging from 67 to 566 per 100,000 with a significant increase with age and in females [3–5]. These records promoted a renewed awareness of this condition as demonstrated by an increase in research activity and the development of international registries over the past few years [6–8].

The pathophysiology of bronchiectasis might start with either structural airway damage or impaired mucociliary clearance, leading to subsequent chronic bacterial infection and a neutrophilic inflammation, which perpetuates this vicious cycle [9]. Bronchiectasis is the final result of different processes, which explains the extreme heterogeneity of the disease [8]. The clinical spectrum of bronchiectasis includes radiological abnormalities in almost asymptomatic patients as well as diffuse respiratory involvement with severe functional and radiological impairment in frequent exacerbations with high morbidity and mortality. In view of the extreme variety of this condition, different methods have been proposed in
literature to cluster discrete groups of patients sharing common clinical features, biological substrates and outcomes [10–12]. Conflicting results have been proposed with the above analysis and most of the scientific community argues on the implementation of this research in clinical practice [13].

Besides clinical phenotypes, one of the imperative steps in the management of patients with bronchiectasis still remains the evaluation of the underlying etiologies [14]. Most of the international guidelines advocate for a careful evaluation of possible etiologies of bronchiectasis especially those which might be treated or might change patients’ management [15, 16]. The recent guidelines published by the European Respiratory Society suggests a minimum bundle of etiological tests to be performed in adults with a new diagnosis of bronchiectasis, including different blood count, serum immunoglobulins and testing for allergic bronchopulmonary aspergillosis [14]. This conditional recommendation is based on very low quality of evidence and practices to investigate bronchiectasis etiology are highly heterogeneous across European countries [17, 18]. Furthermore, a deep analysis of bronchiectasis etiology might be limited by an extensive and costly bundle of tests, which might be run only in tertiary care centers [17, 18]. Finally, experts agree neither on the definition of some etiologies of bronchiectasis (e.g. post-infective) nor the significance of “cause” vs. “association” vs. “overlap” between bronchiectasis and other diseases (e.g. COPD) [19].

Why rule out cystic fibrosis in adults with bronchiectasis?
Although the scenario concerning the investigation of bronchiectasis etiology is still evolving, both clinical and scientific communities agree on the need to rule out cystic fibrosis (CF). CF is an autosomic recessive disease caused by at least two mutations of a gene encoding a transmembrane chloride channel called Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) involved in regulation of liquid volume and anions on epithelial surfaces.

Ruling out CF in bronchiectasis patients is important in view of clinical, social-economical and psychological consequences. From a clinical perspective, CF is a systemic disease with extra-respiratory manifestations, which benefits from a specific management with a favorable impact on patients’ prognosis and quality of life [20]. CF patients have access to respiratory therapies that patients with bronchiectasis have not formal indication for and those with specific mutations might benefit from new CFTR modulator therapies. From a social-economical perspective, CF patients might benefit from a tertiary-care management in specialized centers, have access to free care in some countries or benefit from a special legislation and proper health insurance plans. From a psychological perspective, CF is a chronic, life-limiting disease with implications for patients’ life plans. CF patients have an increased risk of affected children and might benefit from a referral to genetic counseling.

Although the majority of patients with CF are identified by newborn screening or during childhood, late diagnosis of adults is not infrequent [21]. However, testing for CF is not included in the minimum bundle of investigations recommended by international guidelines on the management of bronchiectasis patients and the exclusion of CF is suggested only in the presence of specific clinical features [14]. These include early age of symptom onset, diffuse bronchiectasis with predominant upper lobe distribution on CT scan, early presence of Staphylococcus aureus, Pseudomonas aeruginosa or Burkholderia cepacia in respiratory cultures, upper airway disease like polyps or chronic sinusitis, extra-respiratory involvement such as recurrent pancreatitis and maldigestion, or male infertility, see Table 1 [14, 16, 22–24].

In addition, there is no agreement across bronchiectasis guidelines on which diagnostic test should be used to exclude CF. While the majority of guidelines refers to sweat chloride measurement and CFTR genetic analysis as diagnostic standards, no hierarchical strategy of testing is suggested. An international consensus on the possible strategy to exclude CF in adults with bronchiectasis is still missing.

The lack of common ground in testing bronchiectasis patients for CF has plenty of clinical and research implications. From a clinical perspective, CF testing seems to be inadequate among bronchiectasis patients. The national British Thoracic Society bronchiectasis audit reported testing for CF in 12% of the population [18], while this percentage was even lower (5.5%) in a similar audit performed in Italy [17].

From a research perspective, several randomized controlled trials (RCTs) in bronchiectasis failed to meet their primary end-points and one of the reason might be because they did not account for the disease heterogeneity [25]. This is especially true looking at the exclusion criteria listed in bronchiectasis RCTs over the past 15 years. Only five out of fifty-one trials excluded CF according to either sweat test or genetic analysis, while the majority of the RCTs reported excluding CF patients only according to past medical history [26–30]. Someone could speculate that some of these studies might have included adult patients with mild or even severe CF due to weakness in their exclusion criteria, thus increasing heterogeneity in study population.

How to rule out CF in adults with bronchiectasis?
Nowadays, most CF cases are easily detected by newborn screening and diagnoses occur in clinically
asymptomatic infants [31]. On the contrary, diagnosis of CF in adults can be challenging because of the heterogeneity of clinical manifestations resulting from highly variable levels of CFTR dysfunction and differential exposure to environmental factors [32]. Recently, guidelines for CF diagnosis have been reformulated by an expert committee designated by the United States CF Foundation [33]. According to this document, CF is established when a subject shows either positive newborn screening results or clinical manifestations consistent with the disease and evidence of CFTR dysfunction. The latter can be either sweat chloride test or CFTR genetic analysis or CFTR electrophysiologic tests. All CF patients should have a sweat test and CFTR gene analysis performed. CF is unlikely in the presence of a negative sweat test, but individuals with sweat chloride < 30 mmol/L, i.e. negative, may still have CF. The absence of two CF-causing CFTR mutations does not exclude the diagnosis of CF. If only one mutation is identified, an extended CFTR genetic analysis may be taken into account. In adult patients without classical CF diagnostic criteria, a CFTR-related disorder (CFTR-RD) might be considered. According to the last recommendations edited in 2011, a CFTR-RD is defined as a clinical entity associated with CFTR dysfunction that does not fulfill the diagnostic criteria for CF [34]. CFTR-RD is usually related with three major clinical phenotypes: CBAVD (congenital bilateral absence of the vas deferens) with CFTR dysfunction, acute recurrent pancreatitis with CFTR dysfunction and disseminated bronchiectasis with CFTR dysfunction.

The most widely used test in clinical practice to diagnose CF/CFTR-RD are listed in Table 2 and reported below in details.

### Table 1: When and how rule out CF according to existing bronchiectasis guidelines

| Guidelines | When | How |
|------------|------|-----|
| ERS 2017 [14] | Selected adults including those with any of the following: young adults; upper lobe predominance of bronchiectasis on chest CT; the presence of nasal polypsis and/or chronic rhinosinusitis; recurrent pancreatitis; male primary infertility and/or malabsorption | Sweat chloride, other biomarkers of CFTR activity and CFTR mutation analysis |
| Pulmonology Portuguese Society, 2016 [16] | All children and selected adults (no further specified) | Two measurements of sweat chloride and CFTR mutation analysis |
| British Thoracic Society, 2010 [22] | All children and selected adults including those with any of the following: adults up to the age of 40; age at presentation > 40 years and no other identified cause; persistent isolation of *Staphylococcus aureus* in the sputum; features of malabsorption; male primary infertility; upper lobe bronchiectasis; a history of childhood steatorrhea. | Two measurements of sweat chloride and CFTR mutation analysis |
| Normativa SEPAR, 2008 [23] | Selected adults | Sweat chloride, nasal potential difference, CFTR mutation analysis test |
| Thoracic Society of Australia and New Zealand, 2015 [24] | All children and selected adults (no further specified) | Sweat test |

### Table 2: Comparison among different tests to measure cystic fibrosis transmembrane conductance regulator (CFTR) ion channel activity

| Test | Qualitative | Quantitative | Validated | Clinical | Research |
|------|-------------|--------------|-----------|----------|----------|
| Sweat test | X | | X | | X |
| CFTR gene analysis | X | | X | | X |
| NPD | X | | X | | X |
| ICM | X | | X | | X |
| Ratiometric sweat secretion optical test | X | | X | | X |
| Monocyte assay | X | | X | | X |

*CFTR* cystic fibrosis transmembrane conductance regulator; *NPD* nasal potential difference; *ICM* intestinal current measurement

### Sweat test

Measurement of chloride after sweat induction via pilocarpine iontophoresis is the first-line test to diagnose CF [33]. A chloride concentration above 59 mmol/L is used to define a positive sweat test, while values between 30 and 59 mmol/L are deemed inconclusive and call for further evaluations [33].

### CFTR gene analysis

More than 2000 different mutations in CFTR gene have been reported (http://www.genet.sickkids.on.ca/cftr/app) and standard mutation panels contain the most common CF-causing mutations (variable coverage depending on
CFTR Electrophysiologic testing
Nasal potential difference (NPD) and intestinal current measurement (ICM) are used when sweat tests and mutation analysis are inconclusive and the clinical suspicion persists [33, 35]. NPD is an in vivo test of CFTR functionality by measuring nasal transmucosal voltage potential difference, both in basal conditions and after exposure to different chemicals [36]. ICM is an ex vivo test of CFTR function based on the measurement of transepithelial ion transport in rectal biopsies [37]. Both tests are complex to perform and interpret and are available only in highly specialized centers.

New assays
Ratiometric sweat secretion optical test is intended to assess CFTR function in vivo by comparison of CFTR-dependent and CFTR-independent sweat secretion [38]. Present versions of the test have been able to discriminate among controls, heterozygotes and CF groups showing a continuum in CFTR impairment [39, 40] CFTR is detectable and is functional in human monocytes. The analysis of cell membrane potential changes after the administration of CFTR agonists is lower in CFTR heterozygous carriers and absent in monocytes isolated from CF patients [41]. Correlation with CFTR activity in epithelia is still unclear and further studies are necessary to understand the full potential of this approach.

Physicians taking care of bronchiectasis patients should be aware that all the above tests might have some limitations in the adult population [42, 43]. Sweat test may be not conclusive and intermediate results may be due to residual CFTR functionality as well as environmental factors (e.g. climate, diet) or test variability [42]. In previous reports sweat chloride concentrations appeared to gradually increase during life [43, 44]. In 2013 Traeger and colleagues described 13,782 sweat test performed over 20 years in a single center and reported a peak during middle age, followed by a decrease among elderly subjects [45]. Furthermore, a cut-off of 30 mmol/L for the definition of ‘CF unlikely’ is still debated because it just lies above the median values for sweat chloride in this population, possibly resulting in a greater number of subjects with ambiguous positive results [45]. Finally, over the last decades sweat test has been largely used among infants, children and younger adults, but a validation in elderly population is still lacking.

Diagnostic accuracy of genetic analysis depends on the testing strategy. CFTR gene panels can be designed to be high in specificity, as they test only for CF-causing mutations, at the cost of a relatively lower sensitivity. Sequencing and testing for deletion/duplication increase sensitivity, but reduce specificity by identifying CFTR variants of unknown clinical meaning.

NPD is affected by a very high intra-test variability and several protocol variations and scores for interpretation are reported among different centers [46, 47]. Furthermore, this method needs an experienced operator (hundreds of tests performed), thus limiting a larger use [48]. ICM has been performed following different protocols and, although discussed, it is not present in current diagnostic algorithm and criteria [33, 37]: validation and reference data have been reported [49]. Standard operating procedures of both NPD and ICM are currently available from European Cystic Fibrosis Society (https://www.ecfs.eu/ecfs_dnwg).

The new assays as ratiometric sweat secretion optical test have not been validated yet in clinical practice and they are currently used in translational research. Figure 1 reports a flow-chart for when and how to test CF in people with bronchiectasis.

Implications for future research
Over the last decades, different investigators evaluated the role of CFTR in adults with bronchiectasis. Increased frequency of a single CF-causing mutation in azospermic men was firstly reported by Dumur in 1990 [50]. Since then, a number of papers have been published to investigate the relationship between the presence of a single CFTR mutation and the presence of diffuse bronchiectasis, demonstrating that a CFTR heterozygous condition is more frequent in bronchiectasis patients with normal sweat test in comparison to the general population [51–54]. However, although a diagnosis of CF should be pursued in reason to clinical or social implication, a further speculation on cost/benefit is now needed. The question about how many adults with bronchiectasis need to be tested in order to have a CF diagnosis still remains unanswered. Two scenarios are possible: patients older than 60 years old might not benefit from CF testing in consideration of low catch rate and poor impact on treatment and prognosis; otherwise, CF testing will become cheaper in the future and CFTR screening could be considered.
Also interesting for the discussion is the hypothesis that even a single mutation in CFTR gene may contribute to the development of lung disease. On this side, it has been speculated that bronchiectasis may derive from a complex multifactorial interaction between genetic risk factors and environment. Other genes, so far unidentified, are likely to interact with CFTR activity in the development of the disease; in particular, altered sodium homeostasis due to mutations in ENaC channel is still poorly understood but may play a contributive role [55, 56].

Next step in translational research could be the implementation of a lung genetic panel in bronchiectasis. The strengths of this panel would be a careful selection of genes based on current literature and the inclusion of all those mutations known to be target of new genetic modifiers as well as genes involved in lung inflammation. This approach could lead to new treatments based on better molecular understanding and different therapeutic targets. An individualized approach is necessary to understand the occurrence and contribution of ion channel functional status in bronchiectasis with the aim to evaluate the overall functionality of CFTR and, possibly, other ion channels. As factors not covered by the sequencing of the coding region and the exon/intron junctions could also influence CFTR function, even a sophisticated mutation analysis alone might not identify functionally relevant alterations. Recent developments in the field of stem cell research permit the collection of renewable tissue expressing CFTR and a detailed study of its channel function in organoids derived from minimally invasive rectal biopsies [57]. The use of respiratory cells derived from nasal brush can be envisioned in the near future [58]. These approaches might permit to identify previously undetected alteration in channel homeostasis and unravel novel mechanism/s of disease.

**Conclusions**

Ruling out CF is a cornerstone in etiological screening for patients with bronchiectasis and should be
implemented in usual work-up for investigating bronchiectasis etiology. CFTR mutations, often with unclear pathogenic effect, have been reported with higher frequency among patients with bronchiectasis. Possibly, a single mutation in CFTR combined with other genetic and environmental factors might be involved in the pathogenesis of bronchiectasis. Further studies on CFTR expression in human lung and translational research might elucidate the role of CFTR in bronchiectasis.

Availability of data and materials
Not applicable.

Authors’ contribution
Conception and design: SA and AG. Analysis and interpretation: SA, BA, FB, CC and AG. Drafting the manuscript: AG. All authors participated in writing and revising the article prior to submission. All authors read and approved the final manuscript.

Funding
Not applicable. Publication costs of this article will be funded by Novamedia and Italian Respiratory Society (IRS).

About this supplement
This article has been published as part of Multidisciplinary Respiratory Medicine Volume 13 Supplement 1, 2018: Bronchiectasis: still an orphan disease?. The full contents of the supplement are available online at https://mrmjournal.biomedcentral.com/articles/supplements/volume-13-supplement-1.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests. Prof. Francesco Blasi is Editor-in-Chief of Multidisciplinary Respiratory Medicine, whereas Prof. Stefano Aliberti is Associate editor of Multidisciplinary Respiratory Medicine and Guest Editor of the Supplement on Bronchiectasis.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Pathophysiology and Transplantation, University of Milan, Internal Medicine Department, Respiratory Unit and Cystic Fibrosis Adult Center, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Via Francesco Sforza 35, 20122 Milan, Italy. 2Medical Genetics Laboratory, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy. 3USOSD Genetica Medica, Medical Genetics Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy. 4Department of Otolaryngology and Head and Neck Surgery, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Department of Clinical Sciences and Community Health, University of Milan, 20122 Milan, Italy. 5Centro Fibrosi Cistica, Azienda Ospedaliera Universitaria Integrata, Verona, Italy. 6Dipartimento di Patologia e Diagnostica, Università di Verona, Verona, Italy. 7Department of Otolaryngology and Head and Neck Surgery, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy. 8Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy. 9Molecular Medicine Department, University of Pavia, Viale Taramelli 3/b, 27100 Pavia, Italy.

Published: 9 August 2018

References
1. Chalmers JD, Aliberti S, Blasi F. Management of bronchiectasis in adults. Eur Respir J. 2015;45:1446–62.
2. Quint JK, Millet ERC, Joshi M, Navaratnam V, Thomas SL, Hurst JR, et al. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study. Eur Respir J. 2016;47(1):186–93.
3. Montesagudo M, Rodriguez-Blanco T, Barrechequers M, Simonet P, Miravitlles M. Prevalence and incidence of bronchiectasis in Catalonia, Spain: a population-based study. Respir Med. 2016;121:26–31.
4. Ringshausen FC, de Roux A, Diel R, Hohmann D, Welte T, Rademacher J. Bronchiectasis in Germany: a population-based estimation of disease prevalence. Eur Respir J. 2015;46(6):1805–7.
5. Weycker D, Edelsberg J, Oster G, Tino G. Prevalence and economic burden of bronchiectasis. Clin Pulm Med. 2005;12:205–9.
6. Aksamit TR, O’Donnell AE, Barker A, Olivier KN, Winthrop KL, Daniels MLA, et al. Bronchiectasis research registry consortium. Adult patients with bronchiectasis: a first look at the US bronchiectasis research registry. Chest. 2017;151(5):982–92.
7. Aliberti S, Mayserfeld S, Polverino E, De Soyaza A, Loebinger MR, Menendez R, et al. Research priorities in bronchiectasis: a consensus statement from the EMBARC clinical research collaboration. Eur Respir J. 2016;48(3):642–47.
8. Chalmers JD, Aliberti S, Polverino E, Vendrell M, Crichton M, Loebinger M, et al. The EMBARC European bronchiectasis registry: protocol for an international observational study. ERI Open Res. 2016 Jan 20(1).
9. Cole PJ. Inflammation: a two-edged sword—the model of bronchiectasis. Eur J Respir Dis Suppl. 1986;176:7–15.
10. Aliberti S, Lonni S, Dore S, McDonnell MJ, Goeminne PC, Dimakou K, et al. Clinical phenotypes in adult patients with bronchiectasis. Eur Respir J. 2016;47(4):1113–22.
11. Guan WJ, Jiang M, Gao YH, Li HW, Xu G, Zheng JP, et al. Unsupervised learning technique identifies bronchiectasis phenotypes with distinct clinical characteristics. Int J Tuberc Lung Dis. 2016;20(3):402–10.
12. Martínez-García MA, Vendrell M, Gírond R, Márquez-Caro L, de la Rosa Carrillo D, de Gracia J, et al. The multiple faces of non-cystic fibrosis bronchiectasis: a cluster analysis approach. Ann Am Thorac Soc. 2016;13(9):1468–75.
13. Smith DJ. Phenotyping bronchiectasis: is it all about sputum and infection? Eur Respir J. 2016;47(4):1037–9.
14. Polverino E, Goeminne PC, McDonnell MJ, Aliberti S, Marshall SE, Loebinger MR, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017;50:700629.
15. Lonni S, Chalmers JD, Goeminne PC, McDonnell MJ, Dimakou K, De Soyaza A, et al. Etiology of non-cystic fibrosis bronchiectasis in adults and its correlation to disease severity. Ann Am Thorac Soc. 2015;12(12):1764–70.
16. Pulmonology Portuguese Society Bronchiectasis Study Group. Recommendations for aetiological diagnosis of bronchiectasis. Rev Port Pneumol. 2016;22(4):222–35.
17. Aliberti S, Hill AT, Mantero M, Battaglia S, Centanni S, Lo Cicero S, et al. Quality standards for the management of bronchiectasis in Italy: a national audit. Eur Respir J. 2016;48(1):244–8.
18. Hill AT, Rouat C, Welham S. National BTS bronchiectasis audit 2012: is the quality standard being adhered to in adult secondary care? Thorax. 2014; 69(3):292–4.
19. Amati F, Franchesi E, Gramage M, Chalmers JD, Aliberti S. Investigating the etiology of bronchiectasis: you do not find what you do not look for. Respiration. 2017;93(3):228–9.
20. Elborn JS. Cystic fibrosis. Lancet. 2016;388(10059):2519–31.
21. Rodman DM, Polis JM, Heltithe SL, Sontag MK, Chacon C, Rodman RV, et al. Late diagnosis defines a unique population of long-term survivors of cystic fibrosis. Am J Respir Crit Care Med. 2005;171(6):621–6.
22. Pasteur MC, Bilton D, Hill AT. British Thoracic Society bronchiectasis non-CF guideline group. British Thoracic Society guideline for non-CF bronchiectasis. Thorax. 2010;65(Suppl 1):1–58.
23. Vendrell M, De Gracia J, Oliveira C, Martinez MA, Girón R, Márquez-Caro L, et al. Diagnosis and treatment of bronchiectasis. Spanish Society of Pneumology and Thoracic Surgery Arch Broncopneumol. 2008;44:629–40.
24. Chang AB, Bell SC, Byrnes CA, Grimwood K, Holmes PW, King PT, et al. Chronic supplicative lung disease (CSLD) and bronchiectasis in children and adults in Australian and New Zealand: Thoracic Society of Australia and New Zealand.
Zealand and Australian Lung Foundation position statement. Med J Aust. 2010;193(6):356–6.
25. Chalmers JD, McDonnell MJ, Rutherford R, Davidson J, Finch S, Crichton M, et al. The generalizability of bronchiectasis randomized controlled trials: a multicentre cohort study. Respir Med. 2016;12:51–8.
26. Hernando R, Drobnic ME, Cruvatt MJ, Ferrer A, Suhel P, Montoro JB, et al. Budesonide efficacy and safety in patients with bronchiectasis not due to cystic fibrosis. Int J Clin Pharm. 2013;24(4):644–50.
27. Murray MP, Pentland JL, Hill AT. A randomised crossover trial of chest physiotherapy in non-cystic fibrosis bronchiectasis. Eur Respir J. 2009;34(5): 1086–92.
28. Murray MP, Govan JR, Doherty CJ, Simpson AJ, Wilkinson TS, Chalmers JD, et al. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2011;183(4):491–9.
29. Diego AD, Mila J, Martinez-Moragón E, Palop M, León M, Cortijo J. Effects of long-term azithromycin therapy on airway oxidative stress markers in non-cystic fibrosis bronchiectasis. Respir Res. 2013;18(7):1056–62.
30. Drobnic ME, Suhel P, Montoro JB, Ferrer A, Omols R. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Ann Pharmacother. 2003;37(1):39–44.
31. Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry. Annual data report. Bethesda. MD: Cystic Fibrosis Foundation; 2014. p. 2015.
32. Sosnay PR, White TB, Farrell PM, Ren CL, Accurso F, Derichs N, et al. Diagnosis of cystic fibrosis in non-screened populations. J Pediatr 2017;181: 552–557.e2.
33. Farrell PM, White TB, Ren CL, Hemstreet SE, Accurso F, Derichs N, et al. Diagnosis of cystic fibrosis: consensus guidelines from the Cystic Fibrosis Foundation. J Pediatr. 2017;181:S54–S51.e1.
34. Bomberi C, Claustres M, De Boeck K, Derichs N, Dodge J, Girodon E, et al. Recommendations for the classification of diseases as CFTR-related disorders. J Cyst Fibros. 2011;10(Suppl 2):S86–102.
35. Ooi CY, Dupuis A, Gonska T, Ellis L, Ni A, Jarvi K, et al. Does integration of various ion channel measurements improve diagnostic performance in cystic fibrosis? Ann Am Thorac Soc. 2014;11(4):562–70.
36. Yaako Y, Kerem E, Yahay Y, Rivlin J, Blau H, Bentur L, et al. Reproducibility of nasal potential difference measurements in cystic fibrosis. Chest. 2007; 132(4):129–19.
37. De Boeck K, Derichs N, Fajac I, de Jonge HR, Bronsveld I, Sermet I, et al. New clinical diagnostic procedures for cystic fibrosis in Europe. J Cyst Fibros. 2011;10(Suppl 2):S53–66.
38. Sato K, Sato F. Defective beta adrenergic response of cystic fibrosis sweat glands in vivo and in vitro. J Clin Invest. 1984;73:1763–71.
39. Wine JJ, Char JE, Chen J, Choi HJ, Dunn C, Fristee B, et al. In vivo readout of CFTR function: ratiometric measurement of CFTR-dependent secretion by individual, identifiable human sweat glands. PLoS One. 2013;8(10):e77114.
40. Bergamini G, Tridello G, Calcaterra E, Ceri S, Tagliasacchi M, Bianchi F, et al. Ratiometric sweat secretion optical test in cystic fibrosis, carriers and healthy subjects. J Cyst Fibros. 2017 Dec 29. pii: S156987911730981-5.
41. Soro C, Buffelli M, Angiani C, Etterre M, Johansson J, Vezzalini M, et al. Defective CFTR expression and function are detectable in blood monocytes: development of a new blood test for cystic fibrosis. PLoS One. 2011;6(7):e22212.
42. Collaco JM, Blackman SM, Ranaig K, Corvil H, Rommens JM, Pace RG, et al. Sources of variation in sweat chloride measurements in cystic fibrosis. Am J Respir Crit Care Med. 2016;194(11):1375–82.
43. Hall SK, Stableforth DE, Green A. Sweat sodium and chloride concentrations—essential criteria for the diagnosis of cystic fibrosis in adults. Ann Clin Biochem. 1990;27(Pt 4):318–20.
44. Kirk JM, Westwood A. Interpretation of sweat sodium results—the effect of patient age. Ann Clin Biochem. 1989;26(Pt 1):38–43.
45. Traeger N, Shi O, Dazor AJ. Relationship between sweat chloride, sodium, and age in clinically obtained samples. J Cyst Fibros. 2014;13(10):1–4.
46. Naehrlch L, Ballmann M, Davies J, Derichs N, Gonska T, Hjelte L, et al. Nasal potential difference measurements in diagnosis of cystic fibrosis: an international survey. J Cyst Fibros. 2014 Jan;13(1):24–8.
47. Tridello G, Menin L, Pintani E, Bergamini G, Assael BM, Melotti P. Nasal potential difference outcomes support diagnostic decisions in cystic fibrosis. J Cyst Fibros. 2016;15(5):S579–82.
48. Ahrens RC, Standaert FA, Launspach J, Han SH, Teresi ME, Atikien ML, et al. Use of nasal potential difference and sweat chloride as outcome measures in multicenter clinical trials in subjects with cystic fibrosis. Ped Pulmonol. 2002;33:142–50.
49. Derichs N, Sanz J, Von Kanel T, Stolpe C, Zapf A, Tümmler B, et al. Intestinal current measurement for diagnostic classification of patients with questionable cystic fibrosis: validation and reference data. Thorax. 2010; 65(7):594–9.
50. Dumur V, Gervais R, Rigot JM, Lafitte JJ, Manouvrier S, Biserte J, et al. Abnormal distribution of CF delta F508 allele in azoospermic men with congenital aplasia of epididymis and vas deferens. Lancet. 1990;336(8713):512.
51. Girodon E, Cazeneuve C, Lebargy F, Chinet T, Costes B, Ghanem N, et al. CFTR gene mutations in adults with disseminated bronchiectasis. Eur J Hum Genet. 1997;5:149–55.
52. Bomberi C, Benetazzo M, Saccamoni A, Belpini F, Gile L, Luissetti M, et al. Complete mutational screening of the CFTR gene in 120 patients with pulmonary disease. Hum Genet. 1998;103:718–22.
53. Pasteur MC, Hellowell SM, Houghton SJ, Webb SC, Foweraker JE, Coulind RA, et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med. 2000;162:1277–84.
54. Tzetsis M, Effthymiadou A, Strofilas S, synchou P, Dimakou A, Poulou E, et al. CFTR gene mutations—including three novel nucleotide substitutions and haplotype background in patients with asthma, disseminated bronchiectasis and chronic obstructive pulmonary disease. Hum Genet. 2001;108(3):216–21.
55. Rademacher J, Schulz A, Hedfeldt S, Stankie F, Ringshausen F, Welte T, et al. Nasal potential difference of carriers of the W4993R ENaC variant with non-cystic fibrosis bronchiectasis. Eur Respir J. 2016;47(1):322–4.
56. Fajac I, Vel M, Sublemontier S, Hubert D, Bienvenu T. Could a defective epithelial sodium channel lead to bronchiectasis. Respir Res. 2008;9:46.
57. Dekkers JF, Borkers G, Kruiselbrink E, Vorik A, de Jonge HR, Janssens HM, et al. Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis. Sci Transl Med. 2016 22; 8(344):344ra84.
58. Brewington JJ, Filbrandt ET, LaRosa FJ 3rd, Ostmann AJ, Streecker LM, Saczynski RD, et al. Detection of CFTR function and modulation in primary human nasal cell spheroids. J Cyst Fibros. 2018;17(1):126–33.

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions